Molecular Formula | C23H36N2O4 |
Molar Mass | 404.54 |
Density | 1.123±0.06 g/cm3(Predicted) |
Melting Point | 87-92°C |
Boling Point | 615.5±55.0 °C(Predicted) |
Solubility | 10 mM in DMSO |
Appearance | Solid |
Color | White to Off-White |
pKa | 13.45±0.20(Predicted) |
Storage Condition | 2-8°C |
In vitro study | Eliglustat tartrate is an inhibitor of glucosylceramide synthetase, which catalyzes the formation of glucosylceramide from UDP-glucose and ceramide. Eliglustat tartrate is highly specific for the inhibition of this enzyme and has limited or even no inhibitory activity against a variety of other glycosidases. In addition, 10 μm of Eliglustat tartrate had no inhibitory effect on sucrase and maltase. |
In vivo study | Preclinical studies in normal mice, rats, dogs, by intravenous and oral routes of administration (Eliglustat Tartrate), in the spleen, the content of glucose in kidney and liver was significantly decreased. In rodents, Eliglustat Tartrate is rapidly metabolized in vivo with an in vivo half-life of 15-45 minutes. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.472 ml | 12.36 ml | 24.719 ml |
5 mM | 0.494 ml | 2.472 ml | 4.944 ml |
10 mM | 0.247 ml | 1.236 ml | 2.472 ml |
5 mM | 0.049 ml | 0.247 ml | 0.494 ml |